Cargando…
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
BACKGROUND: CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated. METHODS: Peripheral blood from HLA-A*0201-positive patients with advanced melanoma receiving tremelimumab...
Autores principales: | Comin-Anduix, Begoña, Lee, Yohan, Jalil, Jason, Algazi, Alain, de la Rocha, Pilar, Camacho, Luis H, Bozon, Viviana A, Bulanhagui, Cecile A, Seja, Elisabeth, Villanueva, Arturo, Straatsma, Bradley R, Gualberto, Antonio, Economou, James S, Glaspy, John A, Gomez-Navarro, Jesus, Ribas, Antoni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2412852/ https://www.ncbi.nlm.nih.gov/pubmed/18452610 http://dx.doi.org/10.1186/1479-5876-6-22 |
Ejemplares similares
-
Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016) -
Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013) -
Tremelimumab
Publicado: (2012) -
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
por: Ribas, Antoni, et al.
Publicado: (2012) -
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)